Results 101 to 110 of about 67,160 (259)

Longitudinal follow up of patients with scleroderma sine scleroderma

open access: yes, 2018
Introduction Scleroderma is an autoimmune disease characterized by inflammation, vasculopathy, and fibrosis. Scleroderma Sine Scleroderma is a subtype of scleroderma in which there is autoantibody positivity as well as internal organ involvement ...
Shanmugam, Victoria K.   +3 more
core  

Proteo‐transcriptomic insights into the venom composition of the ectoparasitoid Eupelmus urozonus

open access: yesPest Management Science, EarlyView.
Integrated venom‐gland transcriptomics and venom proteomics of Eupelmus urozonus identified 316 venom proteins, including 75 secreted candidates, revealing diverse hydrolases, proteases/inhibitors and many uncharacterized effectors. Abstract BACKGROUND Ectoparasitoid venoms are ‘cocktails’ of bioactive molecules injected during oviposition to paralyze ...
Federica De Stefano   +7 more
wiley   +1 more source

Scleroderma [PDF]

open access: yesProceedings of the Royal Society of Medicine, 1956
M, FEIWEL, C D, CALNAN
openaire   +2 more sources

Histological Changes of Linear Scleroderma “en Coup de Sabre”

open access: yes, 2014
Introduction. Scleroderma is a chronic disease of unknown aetiology characterized by skin fibrosis and is divided into two clinical entities: localized scleroderma and systemic sclerosis.
Tophuria D.   +3 more
core   +1 more source

Eosinophilic Oesophagitis and Incidence of Gastrointestinal Cancer: A Population‐Based Cohort Study

open access: yesAlimentary Pharmacology &Therapeutics, EarlyView.
Among 9115 patients with eosinophilic oesophagitis in Denmark, excess gastrointestinal cancer in the first year after diagnosis most likely reflected diagnostic work‐up. Beyond 1 year, oesophageal adenocarcinoma and hepatocellular carcinoma remained more frequent than expected; most patients with oesophageal cancer had prior Barrett's oesophagus ...
Gencer Kurt   +4 more
wiley   +1 more source

Scleroderma [PDF]

open access: yesEar, Nose & Throat Journal, 2011
Michele P, Morrison   +2 more
openaire   +2 more sources

Changes in Metabolic and Blood Pressure Outcomes With Semaglutide Across Chronic Kidney Disease Stages: A Post Hoc Analysis of the FLOW Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims To assess changes in glycated haemoglobin (HbA1c), body weight, and systolic/diastolic blood pressure (SBP/DBP) by chronic kidney disease (CKD) and albuminuria categories in a post hoc analysis of FLOW, an international, double‐blind, randomized, phase 3b clinical trial of adults with CKD and Type 2 diabetes (T2D).
Allon N. Friedman   +10 more
wiley   +1 more source

Survival among patients with systemic sclerosis‐associated pulmonary arterial hypertension in the Australian scleroderma cohort study

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background and Aims Systemic sclerosis (scleroderma; SSc) patients can develop pulmonary arterial hypertension (PAH), which is a leading cause of death. We sought to evaluate severity, therapeutic strategy and survival of SSc‐PAH in the Australian Scleroderma Cohort Study (ASCS).
Zoe Brown   +13 more
wiley   +1 more source

Rosiglitazone alleviates the persistent fibrotic phenotype of lesional skin scleroderma fibroblasts

open access: yes, 2010
Objective - The transcription factor peroxisome proliferator-activated receptor (PPAR)-γ plays an important role in controlling cell differentiation. The aim of the present study was to examine whether PPAR-γ expression was reduced in skin scleroderma ...
Stratton, R.J.   +5 more
core   +1 more source

Assessing the quality of end‐of‐life care in systemic sclerosis

open access: yesInternal Medicine Journal, EarlyView.
Abstract Background Systemic sclerosis (SSc) is a rare autoimmune disease with the highest mortality among rheumatic diseases, yet little is known about the quality of end‐of‐life care in SSc. Aims To evaluate end‐of‐life care in SSc against the Australian National Consensus Statement's Essential Elements for high‐quality end‐of‐life care and compare ...
Julie McDonald   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy